Recurrent Osteosarcoma Completed Phase 2 Trials for Cixutumumab (DB12250)

Also known as: Osteosarcoma recurrent / Osteogenic sarcoma recurrent

IndicationStatusPhase
DBCOND0028757 (Recurrent Osteosarcoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01614795Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaTreatment
NCT01016015Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone SarcomaTreatment
NCT00831844Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsTreatment